Novan to Report Full Year 2021 Financial Results on February 22, 2022
February 15, 2022 09:00 ET
|
Novan, Inc.
DURHAM, N.C., Feb. 15, 2022 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN), today announced that it will report its full year 2021 financial results on Tuesday, February...
Novan Appoints Brian M. Johnson as Chief Commercial Officer and Receives Conditional FDA Acceptance of Proposed Brand Name KINSOLUS™ for SB206 in Molluscum Contagiosum
November 02, 2021 08:30 ET
|
Novan, Inc.
– Mr. Johnson brings broad commercial expertise with over 30 years of leadership spanning dermatology marketing, sales, sales management, digital marketing and managed care –– Company received...
Novan Announces Inclusion in Russell Microcap® Index
June 24, 2021 08:05 ET
|
Novan, Inc.
DURHAM, N.C., June 24, 2021 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN), today announced that as part of the annual reconstitution of the Russell stock indexes, Novan...
Novan Announces Closing of $40 Million Public Offering of Common Stock
June 21, 2021 16:01 ET
|
Novan, Inc.
DURHAM, N.C., June 21, 2021 (GLOBE NEWSWIRE) -- Novan, Inc. (the “Company" or "Novan") (NASDAQ:NOVN) today announced the closing of the Company's previously announced underwritten public offering...
Novan Announces Pricing of $40 Million Public Offering of Common Stock
June 17, 2021 09:00 ET
|
Novan, Inc.
DURHAM, N.C., June 17, 2021 (GLOBE NEWSWIRE) -- Novan, Inc. (the “Company" or "Novan") (NASDAQ:NOVN) today announced the pricing of the Company's previously announced underwritten public offering...
Novan Announces Proposed Public Offering of Common Stock
June 16, 2021 16:01 ET
|
Novan, Inc.
DURHAM, N.C., June 16, 2021 (GLOBE NEWSWIRE) -- Novan, Inc. (the “Company” or “Novan”) (NASDAQ: NOVN) today announced a proposed underwritten public offering of its common stock (the “Offering”)....
Results from Novan’s Exploratory Studies Further Demonstrate Antimicrobial Effect of NITRICIL™ Platform Technology with NVN4100 in Companion Animal Health
June 07, 2021 08:30 ET
|
Novan, Inc.
– Positive in vitro results demonstrate antimicrobial effect of NVN4100 against a wide variety of bacteria and suggest a promising bactericidal mode of action – – Novel in vivo canine pyoderma model...
Novan Announces 1-for-10 Reverse Stock Split
May 25, 2021 08:00 ET
|
Novan, Inc.
DURHAM, N.C., May 25, 2021 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN), today announced that it has filed a Certificate of Amendment to the Restated Certificate of...
Novan to Present Clinical Data at Annual Meeting of the Society for Investigative Dermatology
April 22, 2021 09:00 ET
|
Novan, Inc.
MORRISVILLE, N.C., April 22, 2021 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN), today announced that data from the Company’s previously completed Phase 3 trials of SB206...
Novan Provides Enrollment Update and Announces New Corporate Headquarters
January 19, 2021 09:00 ET
|
Novan, Inc.
– B-SIMPLE4 pivotal Phase 3 study in molluscum contagiosum reaches 90% enrollment with topline data targeted for Q2 2021 – – Company secures new location to serve as corporate headquarters and to...